Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
25,224,523
-
Total 13F shares
-
4,357,049
-
Share change
-
-78,434
-
Total reported value
-
$5,227,126
-
Put/Call ratio
-
0%
-
Price per share
-
$1.20
-
Number of holders
-
42
-
Value change
-
-$105,085
-
Number of buys
-
13
-
Number of sells
-
14
Institutional Holders of Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) as of Q4 2024
As of 31 Dec 2024,
Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,357,049 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, GRIFFIN ASSET MANAGEMENT, INC., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Cannell & Spears LLC, RENAISSANCE TECHNOLOGIES LLC, TCI Wealth Advisors, Inc., BlackRock, Inc., Cladis Investment Advisory, LLC, and CITADEL ADVISORS LLC.
This page lists
42
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.